logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
G

Giovanni Abbadessa

sanofi, cambridge, massachusetts, united states
H指数:30
被引数:3,510

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia

I期、单臂、开放标签、剂量递增、多中心研究，评估SAR445419（一种现成、离体扩增的异体自然杀伤细胞产品）在复发或难治性急性髓系白血病患者中的应用

cancer immunology, immunotherapy
IF0
2026-04-110
OAAI
Marina Konopleva; Vijaya Raj Bhatt; Ioannis Mantzaris; Abhishek Maiti; Krishna Gundabolu; Jolie Schafer; Kyle Jensen; Rao Saleem; Yi Li; Agata Drewniak; Pierre Bay; Winston Huh; Ozlem Yildirim; Giovanni Abbadessa; Sarah Cooley; Naval Daver
Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study

Isatuximab联合化疗用于复发/难治性急性淋巴细胞白血病或急性髓系白血病的儿科患者：ISAKIDS研究

HemaSphere
IF14.6
2025-10-300
OAAI
André Baruchel; Karsten Nysom; Hyoung Jin Kang; Maria S. Felice; Mariana Bohns Michalowski; Daniel Freigeiro; Sidnei Epelman; Ana Virginia Lopes de Sousa; Elvis Terci Valera; Larissa Moreira; Guy Leverger; Brigitte Nelken; Antonis Kattamis; Carmelo Rizzari; Franca Fagioli; Simone Cesaro; Oscar González-Llano; Jochen Buechner; Willy Quiñones Choque; Joaquin Duarte; Jonas Abrahamsson; Ada Alarcón; Lynn Wang; Sandrine Macé; Corina Oprea; Giovanni Abbadessa; C. Michel Zwaan
Cytokine Release Syndrome Risk Model with T-Cell Engaging Therapies

细胞因子释放综合征风险模型与T细胞结合疗法

Cytotherapy
IF3.2
2025-07-230
PRE
Pénélope Lafeuille; William A. Blumentals; Claire Brulle-Wohlhueter; Weixi Chen; Chao Sang; Sydney Manning; Silvy Saltzman; Jan Canvin; Susan Richards; Cris Kamperschroer; Giovanni Abbadessa; Bhargav Koduru; Aniketh Talwai; Caroline Der-Nigoghossian; Yahav Itzkovich; Rahul Jain; Tanmay Jain; Jacob Aptekar; Stephan A. Grupp
Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)-SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results

I期/ Ib期开放标签研究：HER2靶向T细胞接合剂（TCE）SAR443216在晚期实体瘤患者（pts）中的静脉（IV）剂量递增结果

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Moreno Garcia, V.; Oh, D-Y.; Ryu, M. H.; Calvo, E.; Garralda, E.; Chung, W-P.; Bai, L-Y.; Rojas Laimito, K. I.; Yildirim, O.; Masciari, S.; Mi, G.; Wang, L.; Kanlikilicer, P.; Buday, B.; Rharbaoui, F.; Abbadessa, G.; Dumbrava, E. E.
Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors

I期首次人体剂量递增研究的结果，该研究评估了第一类抗ILT2抗体SAR444881单药及联合pembrolizumab或cetuximab在晚期实体瘤患者中的疗效。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Perets, R.; Stemmer, S. M.; Geva, R.; Golan, T.; Fakih, M.; Cohen, J. E.; Lieu, C.; Jin, Z.; Lorusso, P.; Friedman, I.; Hakim, M.; Ziv, D. Haves; Hashmueli, S.; Mandel, I.; Ben Moshe, T.; Crawford, N.; Abbadessa, G.; Perez, R.; Wu, M.; Borad, M.
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

Tgf β 抑制剂SAR439459作为单药治疗和与cemiplimab联合治疗晚期实体瘤患者的安全性，药代动力学，药效学和抗肿瘤活性: 1/1b期研究的结果

CTS-CLINICAL AND TRANSLATIONAL SCIENCE
IF2.8
2024-06-191
OA
Baranda, Joaquina C.; Robbrecht, Debbie; Sullivan, Ryan; Doger, Bernard; Santoro, Armando; Barve, Minal; Grob, Jean-Jacques; Bechter, Oliver; Vieito, Maria; de Miguel, Maria Jose; Schadendorf, Dirk; Johnson, Melissa; Pouzin, Clemence; Cantalloube, Cathy; Wang, Rui; Lee, Jooyun; Chen, Xiaofei; Demers, Brigitte; Amrate, Amele; Abbadessa, Giovanni; Hodi, F. Stephen
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
IF2.8
2024-02-161
OAAI
Robbrecht, Debbie; Grob, Jean-Jacques; Bechter, Oliver; Simonelli, Matteo; Doger, Bernard; Borbath, Ivan; Butler, Marcus O.; Cheng, Tina; Romano, Patricia Martin; Pons-Tostivint, Elvire; Di Nicola, Massimo; Curigliano, Giuseppe; Ryu, Min-Hee; Rodriguez-Vida, Alejo; Schadendorf, Dirk; Garralda, Elena; Abbadessa, Giovanni; Demers, Brigitte; Amrate, Amele; Wang, Hong; Lee, Joon Sang; Pomponio, Robert; Wang, Rui
HER2-low expression in patients with advanced or metastatic solid tumors

晚期或转移性实体瘤患者的HER2-low表达

ANNALS OF ONCOLOGY
IF65.4
2023-11-0121
PRE
Uzunparmak, B.; Haymaker, C.; Masciari, S.; Wang, L.; Lin, H.; Gorur, A.; Kirby, B.; Cimo, A. -m.; Kennon, A.; Ding, Q.; Urschel, G.; Yuan, Y.; Feng, G.; Rizvi, Y.; Hussain, A.; Zhu, C.; Kim, P.; Abbadessa, G.; Subbiah, V.; Yap, T. A.; Rodon, J.; Piha-Paul, S. A.; Meric-Bernstam, F.; Dumbrava, E. E.
Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute myeloid leukemia (R/R AML), B cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
PRE
Jongen-Lavrencic, M.; Bajel, A.; Garciaz, S.; Maiti, A.; Fleming, S.; De Button, S.; Huls, G. A.; Jensen, K.; Ziti-Ljajic, S.; Draganov, D.; Rotolo, F.; Palu, C.; Courta, J.; Passe-Coutrin, W.; Traudtner, K.; Wagenaar, T.; Abbadessa, G.; Stein, A. Selwyn
A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
CANCER RESEARCH
IF16.6
2023-04-144
PRE
Bechter, Oliver; Loquai, Carmen; Champiat, Stephane; Baurain, Jean Francois; Grob, Jean-Jacques; Utikal, Jochen; Rottey, Sylvie; Berrocal, Alfonso; Hassel, Jessica; Arance, Ana; Sanmamed, Miguel F.; Boers-Sonderen, Marye; Gastman, Brian; Gebhardt, Christoffer; Delafontaine, Brant; Sahin, Ugur; Tureci, Ozlem; Abbadessa, Giovanni; Di Genova, Gianfranco; Brueck, Patrick; Marpadga, Rahul; Lee, Helen; Lebbe, Celeste
Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR'245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors
CANCER RESEARCH
IF16.6
2023-04-040
PRE
Fu, Siqing; Falchook, Gerald S.; Barve, Minal; McKean, Meredith; Tan, Tira J.; Lemech, Charlotte; Chee, Cheng E.; Marina, Neyssa; Abbadessa, Giovanni; Meng, Robin; Rotolo, Federico; Wang, Hong; Deng, Jason; Wang, Wenting; Wang, Rui; Meniawy, Tarek
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
HEMATOLOGICAL ONCOLOGY
IF3.9
2022-10-312
OAAI
Carlo-Stella, Carmelo; Zinzani, Pier Luigi; Sureda, Anna; Araujo, Luis; Casasnovas, Olivier; Carpio, Cecilia; Yeh, Su-Peng; Bouabdallah, Krimo; Cartron, Guillaume; Kim, Won Seog; Cordoba, Raul; Koh, Youngil; Re, Alessandro; Alves, Daniela; Chamuleau, Martine; Le Gouill, Steven; Lopez-Guillermo, Armando; Moreira, Ilidia; van der Poel, Marjolein W. M.; Abbadessa, Giovanni; Meng, Robin; Ji, Ran; Lepine, Lucie; Saleem, Rao; Ribrag, Vincent
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
ESMO OPEN
IF8.3
2022-10-0118
OAAI
Simonelli, M.; Garralda, E.; Eskens, F.; Gil-Martin, M.; Yen, C-J; Obermannova, R.; Chao, Y.; Lonardi, S.; Melichar, B.; Moreno, V; Yu, M-L; Bongiovanni, A.; Calvo, E.; Rottey, S.; Machiels, J-P; Gonzalez-Martin, A.; Paz-Ares, L.; Chang, C-L; Mason, W.; Lin, C-C; Reardon, D. A.; Vieito, M.; Santoro, A.; Meng, R.; Abbadessa, G.; Menas, F.; Lee, H.; Liu, Q.; Combeau, C.; Ternes, N.; Ziti-Ljajic, S.; Massard, C.

研究方向

暂未获取到该数据
B
Brian Schwartz
H 指数:52论文数:198被引数:1.9万
A
Armando Santoro
H 指数:121论文数:1,854被引数:7.7万
R
Robin Meng
H 指数:7论文数:45被引数:411
L
Lorenza Rimassa
H 指数:70论文数:769被引数:2.2万
R
Ronald E. Savage
H 指数:22论文数:60被引数:1,719
M
Maria Lamar
H 指数:12论文数:32被引数:1,290
E
Emiliano Calvo
H 指数:58论文数:671被引数:1.6万
E
Elena Garralda
H 指数:46论文数:729被引数:1.0万
G
Gaël S. Roth
H 指数:21论文数:143被引数:1,225
T
Thomas Decaens
H 指数:44论文数:316被引数:1.3万